

SEPARATION OF FREE AMINO ACIDS AND PRIMARY AMINES USING DAICEL CROWN ETHER COLUMNS: CROWNPAK CR-I(+) AND CROWNPAK CR-I(-)

APPLICATION NOTE

INTRODUCTION

Daicel Corporation recently introduced a new generation of CROWNPAK® chiral selectors that can be used for the separation of free amino acids and primary amines: CROWNPAK CR-I(+) and CR-I(-). These crown ether selectors are immobilized on 5-μm silica support. Immobilization allows use of organic solvents in a wider range for both reversed-phase and normal-phase chromatography modes, thus, enhancing enantioselective resolution of chiral compounds in a shorter analysis time.

The CROWNPAK CR-I(+) and CR-I(-) chiral selectors are complementary to our CHIRALPAK® ZWIX chiral selectors. The complementarity provides a total solution for enantiorecognition of a wide variety of amino acids. For example, CR-I selectors afford challenging separations of asparagine, glutamine and serine.


One important feature of both CHIRALPAK ZWIX and CROWNPAK CR-I chiral selectors is the ability to control the elution order. Typically, use of ZWIX(+) and CR-I(+) columns would lead to the reversal of the elution order for free amino acids eluted from ZWIX(-) and CR-I(-) columns.

EXPERIMENTAL AND DISCUSSION

A CROWNPAK CR-I(+) column, 3.0 mm i.d. x 150 mm, packed with 5-μm particles was used to develop the separation of DL-serine. The mobile phase was a mixture of perchloric acid and acetonitrile.

The CR-I(+) and CR-I(-) selectors are packed in columns of 3.0 mm i.d. and 150 mm long.

SEPARATION OF DL-SERINE ON CROWNPAK CR-I(+)



CHROMATOGRAPHIC CONDITIONS

Column Size:	Daicel CROWNPAK CR-I(+) 3.0 mm i.d. x 150 mm long, 5-μm
Mobile Phase:	HClO ₄ a.q.(pH1.0) / ACN=85/15(v/v)
Flow Rate:	0.1 ml/min
UV Detection:	200 nm
Column Temperature:	25 °C

Note: Recent scientific studies have demonstrated that the brain of Alzheimer's disease patients contain unusually high levels of D-serine. The potential association of the D-serine level with cognitive decline in the patients may lead to the development of a novel and effective biomarker for early detection of the disease.



CHIRAL TECHNOLOGIES, INC.

1475 Dunwoody Drive
Suite 310
West Chester, PA 19380 USA
Tel: 610-594-2100
Fax: 610-594-2325
www.chiraltech.com
email: chiral@cti.daicel.com

CHIRAL TECHNOLOGIES EUROPE

Parc d'Innovation, Bd Gonther d'Andernach
67404 Illkirch Cedex, France
Tel: +33 (0) 388 79 52 00
Fax: +33 (0) 388 66 71 66
www.chiraltech.com
e-mail: cte@chiral.fr

